COPYRIGHT© Jilin Zixin Pharmaceutical Industrial Co.,Ltd.

COPYRIGHT© 2018  吉林紫鑫药业股份有限公司

Independent Director's independent opinion on renewing the 2014 audit institution and independent director's independent opinion

Page view

Jilin Zixin Pharmaceutical Co., Ltd.

Independent director's independent opinion on renewing the 2014 audit institution

In accordance with the "Guiding Opinions on Establishing an Independent Director System in Listed Companies", the "Guidelines for the Governance of Listed Companies" and the "Articles of Association", as an independent director of the company, after reviewing the relevant proposals, the company renewed the appointment of Sinochem The Institute (special general partnership) issued the following independent opinions for the company's 2014 auditors:

Upon examination, Zhongzhun Certified Public Accountants (special general partnership) has rich experience and professionalism in securities business qualifications and auditing of listed companies. In the past cooperation with the company, it provided high-quality audit services for the company. Standardizing the company's financial management has played a positive and constructive role. During his tenure as the company's audit institution, he followed the "China CPA Auditing Standards" and issued independent audit opinions with diligence, due diligence and fairness. In order to ensure the smooth progress of the company's audit work, we unanimously agreed that the company will re-appoint Zhongzheng Certified Public Accountants (special general partnership) as the audit institution of the company's 2014 financial report, and agree to submit it to the company's shareholders meeting for consideration.

 

Signature of Independent Director: Fu Wei   Li Fei   Wang Xu

February 24, 2014

 

 

Jilin Zixin Pharmaceutical Co., Ltd.

Independent Director's independent opinion on the 2013 Internal Control Self-evaluation Report

According to the relevant requirements of the Shenzhen Stock Exchange's Notice on Doing a Good Job in the Disclosure of the 2013 Annual Report of Listed Companies, we acted as an independent director of Jilin Zixin Pharmaceutical Co., Ltd. and conducted the 2013 Self-evaluation Report on Internal Control of the Company. Reviewed and made the following comments on the matter:

The company's internal control system has been basically established and sound. The existing internal control system is in line with the requirements of relevant laws and regulations and securities regulatory authorities in China. It can adapt to the requirements of company management and meet the needs of the current production and operation of the company and the needs of the company. During the reporting period, the company further improved the internal control system, and provided reasonable assurance for the preparation of true and fair financial reports. It can provide the healthy operation of the company's various business activities and the implementation of relevant national laws and regulations and internal rules and regulations. Guarantee.

Since the establishment of the company's internal control system, various systems have been effectively implemented, which has promoted the steady and healthy development of the company. However, the construction of internal control is a long-term work. Due to the inherent limitations of the internal control system, especially the continuous changes in the macro environment and policies and regulations in recent years, the original control activities may not be applicable or errors may occur. The control system is supplemented and improved, and the internal control system including business control, financial management control and information disclosure control is continuously optimized to ensure the realization of the company's strategy and business objectives.

In summary, we believe that the company's “2013 Internal Control Self-Evaluation Report” objectively and truly reflects the establishment and operation of the company's internal control system.

 

Signature of Independent Director: Fu Wei   Li Fei   Wang Xu

February 24, 2014